189
Results-
Press ReleaseAglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncologyCreated on : - Last modified on :Villejuif and Castres, France, November 18th, 2021 – Ribonexus (previously Aglaia Therapeutics), a biotechnology startup developing promising new therapies that can overcome resistance to current targeted therapies in cancer patients, and French pharmaceutical group Pierre Fabre today announce the signing of an exclusive license agreement on a series of Pierre Fabre patented small molecules targeting the Eukaryotic translation initiation factor 4A (eIF4A).
-
Press ReleaseThe SAFE study covered 7 countries and found that people are not paying proper attention to sun protection adviceCreated on : - Last modified on :May is Skin Cancer Detection and Prevention Awareness Month EADV Spring Symposium - May 12–14, 2022. Pierre Fabre Laboratories maintain their commitment to fighting skin cancer: the SAFE study covered 7 countries and found that people are not paying proper attention to sun protection advice.
-
Press ReleaseChanges within the Group Executive CommitteeCreated on : - Last modified on :Castres, 21 September, 2022 - On October 1, Mr. Frédéric Ennabli will be appointed President of the Dermo-Cosmetics & Personal Care Business Unit. As such, Frédéric Ennabli will join the Group’s Executive Committee and will report Mr. Éric Ducournau, Pierre Fabre Group CEO and Pierre Fabre Dermo-Cosmetics CEO. On the same day, Dr. Núria Perez-Cullell will be appointed Vice President of the Medical Affairs and Patient & Consumer Relations department, reporting to Mr. Éric Ducournau, Group CEO.
-
Press ReleasePierre Fabre is taking a minority stake in Gennisium PharmaCreated on : - Last modified on :Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche markets.
-
Press ReleaseCreation of the Green Impact Index ConsortiumCreated on : - Last modified on :25 economic actors representing more than 1,000 companies join forces to develop an Environmental and Social Impact Labelling Scheme for cosmetic and well-being products.
-
Press ReleasePIERRE FABRE INAUGURATES ITS NEW INNOVATION CENTER IN CHINACreated on : - Last modified on :Shanghai, Castres, June 9, 2023 – After France, Japon and Brazil, Pierre Fabre has just inaugurated its new dermo-cosmetics innovation and research center in China: “Pierre Fabre China Innovation Center”. The CIC is based in Shanghai, in the district of Pudong, the nerve center of new technologies and research.
-
Press ReleasePierre Fabre consolidates its unique expertise in dermatology by creating the largest international databaseCreated on : - Last modified on :The ALL project : more than 50,000 people surveyed in 20 countries on 5 continents Castres, June 20 , 2023 - On the occasion of the 25th World Congress of Dermatology (WCD), which will be held in Singapore from July 4 to 7, the Pierre Fabre Patient Relations Department will present the ALL project, a large-scale survey, the largest ever conducted in dermatology.
-
Press ReleasePierre Fabre announces the acquisition of MÊMECreated on : - Last modified on :MÊME, the first dermo-cosmetic brand for patients experiencing the side effects of cancer treatments
-
Press ReleaseTalem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration with Pierre FabreCreated on : - Last modified on :
-
Press ReleaseHervé Hoppenot, Incyte CEO, is appointed on the Board of Pierre Fabre LaboratoriesCreated on : - Last modified on :Castres (France), January 5th, 2024 – President and CEO of the biotechnology company Incyte since 2014, Hervé Hoppenot will bring his extensive pharmaceutical expertise to the Board of Directors of Pierre Fabre Laboratories, particularly in the field of oncology. His appointment comes at a time when Pierre Fabre is preparing to market in the US its allogeneic immunotherapy Ebvallo® which has just been awarded the prestigious Prix Galien for its therapeutic innovation.
We take care of life by designing and developing innovative solutions inspired by consumers and patients, and contributing to the well-being of everyone from health to beauty.